Sign in
Taking people in South AfricaPhase 2/3

Testing Quit-Smoking Treatments for People Living With HIV in South Africa

Tests quit-smoking drugs and counselling in adults living with HIV in South Africa.

Key facts

Who runs it
Johns Hopkins University
Where
Soweto, South AfricaSee the site
Trial code
Registry title
Evaluating Smoking Cessation Interventions for PWH in South Africa
Status
Recruiting
Phase
Phase 2/3
People taking part
660 people, planned
Started
27 Nov 2023
Expected to end
31 Aug 2027
Type of study
Interventional, 16 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Varenicline
  • Nicotine patch
  • Nicotine gum
  • Intensive Behavioral Counselling
  • Peer Counselling
Record updated
19 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults living with HIV in South Africa who currently smoke and are on antiretroviral therapy (ART). It tests ways to help them quit smoking.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Confirmed HIV, taking ART. Current tobacco smoker with 100 or more cigarettes in a lifetime, at least one cigarette daily in the past 30 days, and a positive breath and urine test.
Earlier treatment
Must have taken ART for at least three months in a row, or for four of the past six months. Must not have used stop-smoking counselling or medicine in the past 14 days.
Biomarker or test result
Exhaled breath carbon monoxide of 7 parts per million or higher, and a positive urine cotinine test.

Main reasons for not taking part

  • History of seizures, cancer, heart disease, stroke, heart attack, stomach ulcers, kidney failure or liver failure
  • Pregnant, planning pregnancy in the next four months, breastfeeding, or unwilling to use effective birth control
  • Very severe illness (Karnofsky score of 40 or lower), cognitive problems, psychosis or suicide risk
  • Past bad reaction to varenicline or the nicotine patch
  • Generalized eczema or psoriasis

This trial only enrols participants living with HIV. The registry sentence this rests on: have a confirmed diagnosis of HIV (evidenced by one of: clinic or hospital prescription for combination antiretroviral therapy (ART), or a current ART medication pack that has the patient's name documented thereon) and

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • ≥18 years of age, and
  • attend one of the selected study clinics, and
  • have a confirmed diagnosis of HIV (evidenced by one of: clinic or hospital prescription for combination antiretroviral therapy (ART), or a current ART medication pack that has the patient's name documented thereon) and
  • have been taking ART for at least three consecutive months or evidence of taking ART for four of the past six months (to ensure engagement in care at the recruitment clinic), and
  • are current tobacco smokers (smoked at least 100 cigarettes in the subject's lifetime, smoked at least one cigarette daily in the past 30 days, have exhaled breath carbon monoxide (CO) ≥ 7 parts per million (ppm), and have a positive urine cotinine test), and
  • either own or have household access to a mobile phone, and
  • provide written informed consent

Who cannot take part

  • Currently (within the previous 14 days) receiving or using smoking cessation counselling or pharmacotherapy, or
  • are unable to participate due to severity of medical illness, guided by a Karnofsky score of ≤ 40, or
  • have a history of seizures, cancer, heart disease, stroke, myocardial infarction, stomach ulcers, kidney failure, or liver failure, or
  • have a history of adverse reactions to varenicline or nicotine patch, or
  • have generalized eczema or psoriasis, or
  • have cognitive dysfunction or psychosis as defined by the Mini-International Neuropsychiatric Interview (M.I.N.I.), or
  • have suicide risk as defined by the Columbia-Suicide Severity Rating Scale (C-SSRS), or
  • are pregnant, planning to become pregnant in the next four months, lactating, or are unwilling to use effective birth control, or
  • are not planning to continue to receive care at the clinic for the next 52 weeks, or
  • are a household member of a currently enrolled participant in this trial, or
  • In the opinion of the attending investigator are not a candidate for the clinical trail

This trial is currently available in South Africa.

  • Perinatal HIV Research Unit (PHRU)Soweto, South AfricaContact: Neil Martinson, MD PHDTaking people

About the trial

What the trial wants to find out

The overall objective of the study is to optimize a smoking cessation treatment package for people with HIV (PWH) that can be integrated into existing HIV care in South Africa.

The 16 groups in the trial

  • Intensive Behavioral CounsellingTreatment being tested

    Participants randomized to the Intensive Behavioural Counselling condition will receive in-person intensive (\~45 minutes) behavioural counselling in the clinic at enrolment/baseline and at weeks 2, 4, 8, and 12. Additionally, on non-clinic visit weeks participants will receive (1) one phone call each week from the clinic counsellor, and (2) two text messages each week providing encouragement and advice. \].

  • Peer SupportTreatment being tested

    Participants randomized to receive Peer Support will be engaged by participants' own peer counsellor assigned from Day 0-12 weeks, with in-person visits at least at baseline, weeks 2, 4, 8 and 12. Peer counselling will follow a flexible framework for contact with participants, which will include in-person and phone-based check-ins, depending upon individual participant preference. Peer counsellors will visit the counsellors' assigned participant in-person at participants' home, workplace, or other setting based on participant preference at least during baseline, weeks 2, 4, 8 and 12; additional in-person contact will be provided upon participant request.

    Treatment: Peer Counselling

  • c-NRTTreatment being tested

    A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package. Participants will be provided with education on its use, including where and how to place a patch, strength of patches to use and how to taper, not smoking while using the patch, and using gum ad hoc; the investigators will also discuss possible side effects. Participants will be given a number to call should the participants require assistance, and weekly calls will be made to participants to screen for adverse events and monitor adherence; calls will taper to every other week after four weeks.

    Treatment: Nicotine patch and Nicotine gum

  • VareniclineTreatment being tested

    At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician according to randomization into the varenicline condition and participants will be provided with education on its use. Participants will be instructed to begin taking varenicline one week prior to participants' quit date and for 11 weeks following quit date. Participants will be given a number to call should the participants require assistance, and weekly calls will be made to participants to screen for adverse events and to monitor adherence; calls will taper to every other week after four weeks.

  • ControlNo study treatment, for comparison

    No intervention

  • Varenicline & c-NRTTreatment being tested

    Treatment: Varenicline, Nicotine patch, and Nicotine gum

  • Peer Support & VareniclineTreatment being tested

    Treatment: Varenicline and Peer Counselling

  • c-NRT & Peer SupportTreatment being tested

    Treatment: Nicotine patch, Nicotine gum, and Peer Counselling

  • c-NRT & Peer Support & VareniclineTreatment being tested

    Treatment: Varenicline, Nicotine patch, Nicotine gum, and Peer Counselling

  • Intensive Behavioral Counseling & VareniclineTreatment being tested

    Treatment: Varenicline and Intensive Behavioral Counselling

  • Intensive Behavioral Counseling & c-NRTTreatment being tested

    Treatment: Nicotine patch, Nicotine gum, and Intensive Behavioral Counselling

  • Intensive Behavioral Counseling & Varenicline & c-NRTTreatment being tested

    Treatment: Varenicline, Nicotine patch, Nicotine gum, and Intensive Behavioral Counselling

  • Intensive Behavioral Counseling & Peer SupportTreatment being tested

    Treatment: Intensive Behavioral Counselling and Peer Counselling

  • Intensive Behavioral Counseling & Peer Support & VareniclineTreatment being tested

    Treatment: Varenicline, Intensive Behavioral Counselling, and Peer Counselling

  • Intensive Behavioral Counseling & Peer Support & c-NRTTreatment being tested

    Treatment: Nicotine patch, Nicotine gum, Intensive Behavioral Counselling, and Peer Counselling

  • Intensive Behavioral Counseling & Peer Support & c-NRT & VareniclineTreatment being tested

    Treatment: Varenicline, Nicotine patch, Nicotine gum, Intensive Behavioral Counselling, and Peer Counselling

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluating Smoking Cessation Interventions for PWH in South Africa: Efficacy, Implementation, and Cost-effectiveness
Plain-language title
Testing Quit-Smoking Treatments for People Living With HIV in South AfricaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
19 October 2026